ClinicalTrials.gg
CompletedNCT00734461Updated May 2, 2016

Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse

A Phase 2 interventional study of oxycodone and naltrexone in Opioid-Related Disorders, sponsored by Pain Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-05-02.

Sponsored by Pain Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing oxycodone in Opioid-Related Disorders — 1 open to participants now, 2 under way, none of them phase 3. Oxycodone · Opioid-Related Disorders.

Enrollment
11th of 15
14 · median 30
Started
2007
the only one that year
Phase 2
4 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
1 of 15
Pain Therapeutics

Among the 15 studies testing oxycodone in Opioid-Related Disorders, this one is the 11th largest by enrollment, is the only one that started in 2007, is one of 4 in phase 2, and was the 3rd registered.

Opioid-Related Disorders

1,473 studies on the registry are indexed under Opioid-Related Disorders; 290 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

1 of the 15 studies testing oxycodone in Opioid-Related Disorders is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 210 Opioid-Related Disorders studies recruiting now, 122 (58%) set no upper age limit and 74 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing oxycodone in Opioid-Related Disorders, or all of them as a file.
02

Study summary

This is a single-center, randomized, 7-way crossover, double-blind, active and placebo-controlled study to evaluate the subjective effects of oxycodone combined with ultra-low dose naltrexone in comparison to oxycodone alone in non-physically dependent subjects with a history of opioid abuse. Approximately 14 subjects will be randomized to one of fourteen sequences selected from a balanced 7x7 Latin square design and its mirror image.

Read the detailed description

At the conclusion of a screening period, qualifying subjects with a negative urine drug screen and ethanol breath test will be admitted to an inpatient research unit. After a 24 hour observation period confirming that the subject is not undergoing opioid withdrawal, subjects will randomly receive either 30 mg oxycodone or matching placebo over two consecutive days in a double-blind fashion. The purpose of this oxycodone vs. placebo qualifying period is to select for subjects with a positive drug liking response and to orient subjects to the various scales. Only subjects with a positive response on the visual analog "Liking" scale of at least 20 points higher on active oxycodone vs. placebo will be eligible to continue in the double-blind 7-way crossover study. Fourteen subjects will be randomized to one of fourteen sequences.

Each subject will receive a single dose of one of the following 7 treatments:

Placebo, oxycodone 20 mg, oxycodone 40 mg, oxycodone 20 mg/naltrexone 0.001 mg, oxycodone 40 mg/naltrexone 0.001 mg,oxycodone 20 mg/naltrexone 0.0001 mg, oxycodone 40 mg/naltrexone 0.0001 mg.

Oxycodone and naltrexone will be formulated in combination as a single tablet. All tablets will be identical in appearance. The identity of each treatment will be unknown to all study personnel and subjects.

Immediately prior to and at specified time points after administration of a single dose of study drug, subjects will complete the following subjective scales: visual analog scales (VAS) for any drug effect, high, good effects, bad effects, liking, and sick; and adjective ratings (agonist and antagonist scales). Subjects will also be asked to complete a money versus drug questionnaire at various time points after drug administration. Observers will complete an adjective rating scale. Safety will be monitored by vital signs (heart rate, blood pressure, respiratory rate, and pulse oximetry), adverse events assessments, clinical laboratory tests, physical examinations and electrocardiograms (ECGs). In addition, pupil diameter (measured by photographs) will be obtained to monitor for physiological signs of opioid effects.

The first double-blind dose of study drug will be administered at least 24 hours after the last dose of the two day qualifying period. Dosings will be separated by a washout period of at least 120 hours (see sample calendar in Section 6.5). The observation period for safety will continue for 24 hours following the final dose of study drug.

03

Conditions studied

  • Opioid-Related Disorders

Keywords

  • Non-physically dependent subjects
  • history of opioid abuse
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females who are at least 18 and no more than 65 years of age.
  • The subject is in good health as determined by medical history and physical examination.
  • The subject is willing and able to speak, read, and understand English and provide written .
  • The subject's urine drug screen and ethanol breath test are negative at check-in to the clinic.
  • The subject has a history of polydrug abuse and: Has taken illicit opioids within the last 30 days; and/or Misused/abused prescription opioids within the last 30 days.
  • The subject is willing and able to comply with all testing and requirements defined in the protocol.
  • The subject must agree to refrain from caffeine and xanthine-containing products throughout the study, and to refrain from nicotine from 1 hour prior to each dosing until 4 hours after each dosing.
  • The subject is willing and able to remain at the study site unit for the duration of the study.
  • The subject has a positive response to oxycodone in the blinded qualifying period as defined by a VAS Liking score for oxycodone that is at least 20 points greater than that for placebo.
  • Females who are , physically incapable of childbearing, or practicing an acceptable method of . Acceptable methods of birth control include surgical sterilization, hormonal contraceptives, or double-barrier methods (condom or diaphragm with a spermicidal agent or intrauterine device [IUD]). A negative pregnancy test result must be obtained for all females at screening and at check-in to the clinic.

Exclusion criteria

Exclusion Criteria:

  • The subject has a positive urine drug screen or ethanol breath test at check-in to the clinic.
  • The subject has been taking prescription opioids daily for chronic pain or has been taking illicit or prescription opioids daily for recreational purposes for more than 20 days in the last month.
  • The subject is enrolled in treatment for drug abuse or is actively seeking treatment for drug abuse.
  • The subject has any significant deviations from normal in physical examination, (ECG), or clinical laboratory tests, as evaluated by the investigator.
  • The subject has had a illness within 30 days preceding entry into this study.
  • The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
  • The subject has a history of an allergic reaction to oxycodone or structurally similar compounds (morphine, hydromorphone, hydrocodone, levorphanol, pentazocine, codeine, etc.), naltrexone or other narcotic agonists.
  • The subject has used any prescription medication (besides hormonal ) or recreational drugs within 7 days or over-the-counter (OTC) medication within 48 hours of check-in to the clinic or intends to use any prescription, recreational drugs or OTC medication during the study that may interfere with the evaluation of study medication.
  • The subject has used alcohol, grapefruit, or grapefruit juice 24 hours before check-in to the clinic or intends to use any of these products during the study.
  • The subject is pregnant or breastfeeding.
  • The subject has received an drug within 30 days prior to initiation of this study.
  • The subject exhibits signs/symptoms of opioid withdrawal during the 24-hour observation period after check-in.
  • The subject has a history of hospitalization due to a psychiatric disorder within the previous year or a current major psychiatric disorder. (Substance abuse disorders are not exclusionary).
  • The subject experiences any of the following within 4 hours after administration of oxycodone 30 mg during the blinded qualifying dosing period: adverse events requiring narcotic antagonist administration, emesis, or opioid toxicity (see Section 10.0).
  • The subject is unwilling to reside in the study unit for the inpatient portion of the study or to cooperate fully with the investigator or site personnel.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
14 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo, single dose

    Drug: oxycodone and naltrexone

  • Active comparator
    Oxycodone 20 mg

    Oxycodone 20 mg single dose tablet

    Drug: oxycodone and naltrexone

  • Active comparator
    Oxycodone 40 mg

    Oxycodone 40 mg single dose tablet

    Drug: oxycodone and naltrexone

  • Experimental
    PTI-801 20/.001 mg

    Oxycodone 20 mg / Naltrexone 0.001 mg

    Drug: oxycodone and naltrexone

  • Experimental
    PTI-801 40/.001 mg

    Oxycodone 40 mg / Naltrexone 0.001 mg

    Drug: oxycodone and naltrexone

  • Experimental
    PTI-801 20/.0001 mg

    Oxycodone 40 mg / Naltrexone 0.0001 mg

    Drug: oxycodone and naltrexone

  • Experimental
    PTI-801 40/.0001 mg

    Oxycodone 40 mg / Naltrexone 0.0001 mg

    Drug: oxycodone and naltrexone

Interventions

  • Drugoxycodone and naltrexone

    Drug pages: Oxycodone · Naltrexone

    tablets containing 20 mg or 40 mg oxycodone / tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone

06

What researchers measure

Primary outcomes

  1. The primary objective of this study is to evaluate the subjective effects of PTI-801 formulated with either 0.001 mg naltrexone or 0.0001 mg naltrexone compared to oxycodone alone in individuals with a history of opioid abuse.

    Time frame: At 30, 60, 90, 120, 150, 180 and 210 minutes post-dose

Secondary outcomes

  1. Secondary objectives include determining the safety and physiological effects of single doses of PTI-801 compared to oxycodone following oral administration in individuals with a history of opioid abuse.

    Time frame: At 30, 60, 90, 120, 150, 180 and 210 minutes post-dose

07

Study locations

1 site
  • Behavioral Pharmacology Research Unit
    Baltimore, Maryland 21224-6823, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2008
First posted
Aug 14, 2008
Start
Aug 2007
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results delay requested
Mar 30, 2016
Last update
May 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00734461
Lead sponsor
Pain Therapeutics
Responsible party
Sponsor
First posted
Aug 14, 2008
Start date
Aug 2007
Primary completion
Mar 2009
Completion
Mar 2009
Last update
May 2, 2016

Study contacts

George E Bigelow, PhD
principal investigator · Johns Hopkins School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxycodone · Naltrexone

Start the discussion